SAB Biotherapeutics, Inc.
(NASDAQ: SABS)
SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company, which engages in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. The firm produces human polyclonal immunotherapies and its versatile DiversitAb platform is applicable for unmet needs in human diseases. The company was founded by Eddie J. Sullivan and Christine E. Hamilton in July 2014 and is headquartered in Miami Beach, FL.
3.795 -
-0.005
(-0.13%)
Range
3.775 - 4.450
(17.88%)
Open
4.100
Previous Close
3.800
Bid Price
3.920
Bid Volume
352
Ask Price
3.930
Ask Volume
655
Volume
1,461,769.7
Value
4,046,692
Remark
-
Delayed prices. Updated at 08 May 2026 00:07.
Data powered by
View All Events
Loading Chart...
Please login to view stock data and analysis
